Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents. 2016

Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University , 103 Wenhua Road, Shenhe District, Shenyang 110016, China.

A series of 3,6-diaryl-[1,2,4]triazolo[4,3-b]pyridazines were designed as a class of vinylogous CA-4 analogues. The easily isomerized (Z,E)-butadiene linker of vinylogous CA-4 was replaced by a rigid [1,2,4]triazolo[4,3-b]pyridazine scaffold. Twenty-one target compounds were synthesized and exhibited moderate to potent antiproliferative activity. The compound 4q with a 3-amino-4-methoxyphenyl moiety as the B-ring, comparable to CA-4 (IC50 = 0.009-0.012 μM), displayed the highly active antiproliferative activity against SGC-7901, A549, and HT-1080 cell lines with IC50 values of 0.014, 0.008, and 0.012 μM, respectively. Tubulin polymerization experiments indicated that 4q effectively inhibited tubulin polymerization, and immunostaining assay revealed that 4q significantly disrupted tubulin microtubule dynamics. Moreover, cell cycle studies revealed that compound 4q dramatically arrested cell cycle progression at G2/M phase in A549 cells. Molecular modeling studies showed that 4q could bind to the colchicine binding site on microtubules.

UI MeSH Term Description Entries

Related Publications

Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
March 1990, Farmaco (Societa chimica italiana : 1989),
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
May 2019, Bioorganic chemistry,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
January 2009, Tetrahedron letters,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
May 1981, Journal of medicinal chemistry,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
October 2020, European journal of medicinal chemistry,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
December 1979, Die Pharmazie,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
June 2007, European journal of medicinal chemistry,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
April 2020, Scientific reports,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
January 2010, Acta poloniae pharmaceutica,
Qile Xu, and Yueting Wang, and Jingwen Xu, and Maolin Sun, and Haiqiu Tian, and Daiying Zuo, and Qi Guan, and Kai Bao, and Yingliang Wu, and Weige Zhang
March 1985, Journal of medicinal chemistry,
Copied contents to your clipboard!